chromosome 6 open reading frame 89Genealiases: BRAP · PS1TP5TP1
Q-omics provides the consensus-scored C6orf89 profile across patient tissues and cancer cell-line models. C6orf89 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C6orf89 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, C6orf89 RNA expression shows 20,684 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where C6orf89 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C6orf89 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C6orf89 survival associations across molecular data types. C6orf89 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C6orf89 RNA expression–survival associations across cancer types. High C6orf89 expression shows unfavorable associations in LAML, KICH and BLCA, but favorable associations in KIRC, THYM and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C6orf89 RNA expression.
This table summarizes C6orf89 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C6orf89. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C6orf89 shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in LIHC, HNSC and CHOL. The THCA box plot shows higher C6orf89 RNA expression in normal versus tumor tissue (log2 FC = −1.160, t-test p < 0.001).
This table shows molecular features associated with C6orf89 in patient tissues and cancer cell lines. In patient samples, C6orf89 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, C6orf89 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
